ADC Therapeutics (ADCT) Receivables - Net: 2020-2023
Historic Receivables - Net for ADC Therapeutics (ADCT) over the last 3 years, with Sep 2023 value amounting to $21.2 million.
- ADC Therapeutics' Receivables - Net fell 8.91% to $21.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $21.2 million, marking a year-over-year decrease of 8.91%. This contributed to the annual value of $73.0 million for FY2022, which is 141.48% up from last year.
- According to the latest figures from Q3 2023, ADC Therapeutics' Receivables - Net is $21.2 million, which was down 11.25% from $23.9 million recorded in Q2 2023.
- ADC Therapeutics' 5-year Receivables - Net high stood at $73.0 million for Q4 2022, and its period low was -$1,000 during Q1 2020.
- Moreover, its 3-year median value for Receivables - Net was $22.2 million (2022), whereas its average is $21.6 million.
- In the last 5 years, ADC Therapeutics' Receivables - Net surged by 1,003,411.30% in 2022 and then decreased by 8.91% in 2023.
- ADC Therapeutics' Receivables - Net (Quarterly) stood at -$1,000 in 2020, then reached $30.2 million in 2021, then soared by 141.48% to $73.0 million in 2022, then declined by 8.91% to $21.2 million in 2023.
- Its Receivables - Net stands at $21.2 million for Q3 2023, versus $23.9 million for Q2 2023 and $24.0 million for Q1 2023.